vs

Side-by-side financial comparison of Amarin Corp plc (AMRN) and SOUTHERN FIRST BANCSHARES INC (SFST). Click either name above to swap in a different company.

Amarin Corp plc is the larger business by last-quarter revenue ($45.1M vs $31.8M, roughly 1.4× SOUTHERN FIRST BANCSHARES INC). On growth, SOUTHERN FIRST BANCSHARES INC posted the faster year-over-year revenue change (26.1% vs 7.0%). Over the past eight quarters, SOUTHERN FIRST BANCSHARES INC's revenue compounded faster (22.2% CAGR vs -18.3%).

Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa (AMR-101), a prescription grade omega-3 fatty acid.

First Community Bankshares, Inc. is a $2.43 billion bank holding company and the parent company of First Community Bank of Bluefield, Virginia, in the United States. As of 2012 First Community Bank had 45 locations in Virginia, West Virginia, and North Carolina, and two locations operating as Peoples Community Bank in Tennessee. As of April 21, 2023, First Community had $3.6 billion in assets.

AMRN vs SFST — Head-to-Head

Bigger by revenue
AMRN
AMRN
1.4× larger
AMRN
$45.1M
$31.8M
SFST
Growing faster (revenue YoY)
SFST
SFST
+19.1% gap
SFST
26.1%
7.0%
AMRN
Faster 2-yr revenue CAGR
SFST
SFST
Annualised
SFST
22.2%
-18.3%
AMRN

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
AMRN
AMRN
SFST
SFST
Revenue
$45.1M
$31.8M
Net Profit
$-10.5M
Gross Margin
Operating Margin
35.5%
40.1%
Net Margin
-23.3%
Revenue YoY
7.0%
26.1%
Net Profit YoY
33.0%
EPS (diluted)
$1.19

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AMRN
AMRN
SFST
SFST
Q1 26
$45.1M
Q4 25
$49.2M
$31.8M
Q3 25
$49.7M
$31.1M
Q2 25
$72.7M
$28.6M
Q1 25
$42.0M
$26.5M
Q4 24
$62.3M
$25.2M
Q3 24
$42.3M
$23.8M
Q2 24
$67.5M
$23.1M
Net Profit
AMRN
AMRN
SFST
SFST
Q1 26
$-10.5M
Q4 25
$-1.2M
Q3 25
$-7.7M
$8.7M
Q2 25
$-14.1M
$6.6M
Q1 25
$-15.7M
$5.3M
Q4 24
$-48.6M
Q3 24
$-25.1M
$4.4M
Q2 24
$1.5M
$3.0M
Gross Margin
AMRN
AMRN
SFST
SFST
Q1 26
Q4 25
47.1%
Q3 25
44.7%
Q2 25
69.2%
Q1 25
59.8%
Q4 24
-15.4%
Q3 24
38.5%
Q2 24
63.4%
Operating Margin
AMRN
AMRN
SFST
SFST
Q1 26
35.5%
Q4 25
-12.9%
40.1%
Q3 25
-22.4%
36.4%
Q2 25
-22.0%
30.0%
Q1 25
-39.9%
26.1%
Q4 24
-84.3%
27.3%
Q3 24
-59.5%
24.1%
Q2 24
-0.8%
17.0%
Net Margin
AMRN
AMRN
SFST
SFST
Q1 26
-23.3%
Q4 25
-2.5%
Q3 25
-15.6%
27.8%
Q2 25
-19.4%
23.0%
Q1 25
-37.4%
19.9%
Q4 24
-78.0%
Q3 24
-59.4%
18.4%
Q2 24
2.3%
13.0%
EPS (diluted)
AMRN
AMRN
SFST
SFST
Q1 26
Q4 25
$0.00
$1.19
Q3 25
$-0.02
$1.07
Q2 25
$-0.03
$0.81
Q1 25
$-0.04
$0.65
Q4 24
$-0.12
$0.69
Q3 24
$-0.06
$0.54
Q2 24
$0.00
$0.37

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AMRN
AMRN
SFST
SFST
Cash + ST InvestmentsLiquidity on hand
$307.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$368.7M
Total Assets
$645.8M
$4.4B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AMRN
AMRN
SFST
SFST
Q1 26
$307.8M
Q4 25
$302.6M
Q3 25
$286.6M
Q2 25
$298.7M
Q1 25
$281.8M
Q4 24
$294.2M
Q3 24
$305.7M
Q2 24
$306.7M
Stockholders' Equity
AMRN
AMRN
SFST
SFST
Q1 26
Q4 25
$459.3M
$368.7M
Q3 25
$458.9M
$356.3M
Q2 25
$464.9M
$345.5M
Q1 25
$473.7M
$337.6M
Q4 24
$486.2M
$330.4M
Q3 24
$531.4M
$326.5M
Q2 24
$551.9M
$318.7M
Total Assets
AMRN
AMRN
SFST
SFST
Q1 26
$645.8M
Q4 25
$670.8M
$4.4B
Q3 25
$659.8M
$4.4B
Q2 25
$670.1M
$4.3B
Q1 25
$655.7M
$4.3B
Q4 24
$685.3M
$4.1B
Q3 24
$750.6M
$4.2B
Q2 24
$799.9M
$4.1B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AMRN
AMRN
SFST
SFST
Operating Cash FlowLast quarter
$30.5M
Free Cash FlowOCF − Capex
$29.9M
FCF MarginFCF / Revenue
93.8%
Capex IntensityCapex / Revenue
1.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$62.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AMRN
AMRN
SFST
SFST
Q1 26
Q4 25
$15.3M
$30.5M
Q3 25
$-12.7M
$14.5M
Q2 25
$16.6M
$10.5M
Q1 25
$-12.5M
$7.6M
Q4 24
$-13.3M
$25.6M
Q3 24
$-2.4M
$26.3M
Q2 24
$-2.7M
$4.0M
Free Cash Flow
AMRN
AMRN
SFST
SFST
Q1 26
Q4 25
$29.9M
Q3 25
$14.4M
Q2 25
$10.4M
Q1 25
$7.4M
Q4 24
$24.8M
Q3 24
$26.1M
Q2 24
$3.9M
FCF Margin
AMRN
AMRN
SFST
SFST
Q1 26
Q4 25
93.8%
Q3 25
46.3%
Q2 25
36.3%
Q1 25
28.1%
Q4 24
98.2%
Q3 24
110.0%
Q2 24
16.8%
Capex Intensity
AMRN
AMRN
SFST
SFST
Q1 26
Q4 25
1.8%
Q3 25
0.3%
Q2 25
0.3%
Q1 25
0.5%
Q4 24
3.1%
Q3 24
0.8%
Q2 24
0.4%
Cash Conversion
AMRN
AMRN
SFST
SFST
Q1 26
Q4 25
Q3 25
1.67×
Q2 25
1.59×
Q1 25
1.44×
Q4 24
Q3 24
6.01×
Q2 24
-1.81×
1.32×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AMRN
AMRN

U.S$35.6M79%
Europe$4.9M11%
Rest-of-World (ROW)$2.8M6%
Licensing & Royalties$1.8M4%

SFST
SFST

Segment breakdown not available.

Related Comparisons